Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 25.79%14.27B | -0.56%13.27B | -5.79%12.88B | 10.53%51.43B | 1.83%13.07B | 7.80%11.35B | 17.55%13.34B | 15.65%13.67B | 1.33%46.53B | -0.10%12.84B |
Cost of revenue | 24.97%1.07B | 30.73%1.11B | 18.44%893M | 25.22%3.32B | 15.51%864M | 21.51%853M | 40.07%846M | 26.72%754M | 26.02%2.65B | 29.41%748M |
Gross profit | 25.85%13.21B | -2.68%12.16B | -7.20%11.99B | 9.64%48.11B | 0.98%12.21B | 6.82%10.49B | 16.29%12.49B | 15.06%12.92B | 0.14%43.88B | -1.49%12.09B |
Operating expense | 34.75%9.47B | 38.71%11.57B | -16.49%7.63B | -3.08%33.66B | -19.14%9.15B | -9.22%7.03B | 6.38%8.34B | 16.74%9.14B | 22.20%34.73B | 21.41%11.32B |
Staff costs | 8.80%1.26B | -16.34%1.08B | -5.38%1.3B | -2.71%5.31B | 30.61%1.49B | -18.15%1.16B | -14.16%1.29B | -1.86%1.38B | -12.78%5.46B | -29.38%1.14B |
Selling and administrative expenses | -6.45%870M | -1.86%896M | 15.29%1B | 2.52%3.66B | -1.66%950M | 16.69%930M | 1.56%913M | -4.50%870M | 18.35%3.57B | -0.82%966M |
-General and administrative expense | -6.45%870M | -1.86%896M | 15.29%1B | 2.52%3.66B | -1.66%950M | 16.69%930M | 1.56%913M | -4.50%870M | 18.35%3.57B | -0.82%966M |
Depreciation and amortization | -9.46%794M | -10.11%818M | -8.07%832M | -5.78%3.55B | -6.72%861M | -8.46%877M | -3.09%910M | -4.84%905M | 106.29%3.77B | -4.05%923M |
-Depreciation | -16.25%541M | -16.64%566M | -10.83%601M | -3.49%2.63B | -8.83%630M | -5.83%646M | 1.80%679M | -0.88%674M | 89.96%2.72B | 0.14%691M |
-Amortization | 9.52%253M | 9.09%252M | 0.00%231M | -11.75%924M | -0.43%231M | -15.07%231M | -15.07%231M | -14.76%231M | 165.74%1.05B | -14.71%232M |
Other operating expenses | 61.12%6.55B | 67.89%8.77B | -24.94%4.49B | -3.63%21.13B | -29.39%5.86B | -11.13%4.06B | 16.18%5.23B | 31.18%5.99B | 26.63%21.93B | 43.55%8.29B |
Operating profit | 7.79%3.73B | -85.77%591M | 15.27%4.36B | 57.92%14.45B | 296.50%3.06B | 66.54%3.46B | 43.04%4.15B | 11.21%3.78B | -40.56%9.15B | -73.86%771M |
Net non-operating interest income (expenses) | 0 | -2,100.00%-80M | 50.00%6M | 0 | 0.00%4M | 4M | ||||
Non-operating interest income | ---- | ---- | ---- | 50.00%6M | ---- | ---- | ---- | ---- | 0.00%4M | ---- |
Total other finance cost | --0 | ---- | ---- | --86M | --0 | --0 | ---- | ---- | ---- | ---- |
Net investment income | 112.43%22M | 68.34%-183M | 4,900.00%50M | -91.61%12M | -44.36%143M | -130.73%-177M | -307.91%-578M | |||
Gain(Loss) on financial instruments designated as cash flow hedges | 23.33%-46M | -35.64%-137M | -81M | 86.57%-87M | 111.42%74M | -60M | -101M | 0 | -648M | -648M |
Gain(Loss) on derecognition of available-for-sale financial assets | -56.89%97M | 73.87%-248M | 36.25%-51M | 0.61%-1.14B | -398.53%-339M | 122.87%225M | -942.86%-949M | -1,042.86%-80M | -2,354.90%-1.15B | -158.62%-68M |
Income from associates and other participating interests | ||||||||||
Special income (charges) | 107.50%6M | 97.17%-9M | -30,900.00%-310M | 89.24%-392M | 103.54%7M | 97.48%-80M | -20.45%-318M | 50.00%-1M | -1,718.67%-3.64B | -560.47%-198M |
Less:Other special charges | -94.52%4M | --9M | 15,400.00%310M | -97.96%70M | -225.00%-5M | -97.70%73M | --0 | 0.00%2M | --3.44B | --4M |
Less:Write off | -242.86%-10M | --0 | --0 | 56.31%322M | -101.03%-2M | --7M | 2,550.00%318M | ---1M | 191.56%206M | 551.16%194M |
Other non-operating income (expenses) | 475.00%120M | -833.33%-28M | -400.00%-57M | 91.76%-22M | 98.04%-6M | -228.00%-32M | 70.00%-3M | -20.83%19M | -3,066.67%-267M | -1,700.00%-306M |
Income before tax | 4.63%3.73B | -96.93%83M | -0.13%3.85B | 290.27%12.75B | 356.21%2.62B | 273.36%3.57B | 0.97%2.71B | 5.18%3.86B | -79.91%3.27B | -130.31%-1.02B |
Income tax | 183.44%1.83B | -2.63%1.37B | -32.33%1.12B | 102.74%5.25B | 205.39%1.53B | 525.00%646M | 45.45%1.41B | 30.79%1.66B | -54.13%2.59B | -65.80%501M |
Net income | -34.93%1.9B | -199.15%-1.29B | 24.24%2.73B | 1,003.68%7.51B | 171.59%1.09B | 253.28%2.92B | -24.17%1.3B | -8.39%2.2B | -93.60%680M | -179.79%-1.52B |
Net income continuous operations | -34.93%1.9B | -199.15%-1.29B | 24.24%2.73B | 1,003.68%7.51B | 171.59%1.09B | 253.28%2.92B | -24.17%1.3B | -8.39%2.2B | -93.60%680M | -179.79%-1.52B |
Noncontrolling interests | -72.41%-50M | -45.45%-48M | -16.13%-72M | 72.93%-144M | 90.00%-20M | 87.66%-29M | 48.44%-33M | -87.88%-62M | -169.72%-532M | -40.85%-200M |
Net income attributable to the company | -33.84%1.95B | -193.31%-1.24B | 24.00%2.8B | 531.11%7.65B | 183.85%1.11B | 276.80%2.95B | -25.06%1.33B | -7.04%2.26B | -87.71%1.21B | -164.54%-1.33B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -33.84%1.95B | -193.31%-1.24B | 24.00%2.8B | 531.11%7.65B | 183.85%1.11B | 276.80%2.95B | -25.06%1.33B | -7.04%2.26B | -87.71%1.21B | -164.54%-1.33B |
Gross dividend payment | ||||||||||
Basic earnings per share | -34.17%16.53 | -194.52%-10.52 | 19.61%23.73 | 513.60%65.41 | 180.02%9.33 | 271.17%25.11 | -28.75%11.13 | -7.16%19.84 | -87.73%10.66 | -164.53%-11.66 |
Diluted earnings per share | -33.86%16.53 | -194.58%-10.5264 | 19.61%23.73 | 515.91%65.41 | 180.02%9.33 | 270.37%24.9938 | -28.47%11.13 | -6.77%19.84 | -87.71%10.62 | -164.85%-11.66 |
Dividend per share | -15.61%8.27 | -64.91%2 | 17.52%11.87 | 56.19%32.8 | 7.2 | 9.8 | -32.94%5.7 | -19.20%10.1 | -59.75%21 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |